J&J's Teclistamab Signals New Era for Myeloma Treatment

BEERSE, BELGIUM – May 29, 2026 – Johnson & Johnson has unveiled pivotal data that could fundamentally reshape the treatment landscape for multiple myeloma, a complex and incurable blood cancer. Results from the Phase 3 MajesTEC-9 study, presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting, show that its bispecific antibody TECVAYLI® (teclistamab) dramatically improves survival outcomes when used as early as the first relapse.

The study, simultaneously published in The New England Journal of Medicine, found that teclistamab reduced the risk of disease progression or death by an unprecedented 71 percent and cut the risk of death by 40 percent compared to current standard-of-care regimens. These striking results position the therapy to become a new standard for patients who have received just one to three prior treatments, offering a powerful new weapon much earlier in the disease course.

A Paradigm Shift for Early Relapse

For years, the most potent immunotherapies have been reserved for patients with heavily pretreated, late-stage multiple myeloma. The MajesTEC-9 findings signal a significant paradigm shift, suggesting that bringing these powerful treatments forward can yield profound benefits.

The trial focused on a particularly challenging patient population whose disease had already proven resistant to frontline therapies. A staggering 85 percent of participants were refractory to anti-CD38 therapy and 79 percent to lenalidomide, two cornerstones of modern myeloma treatment. For this group, effective next-step options are limited, and prognoses are often poor.

“These findings further reinforce teclistamab’s potential to meaningfully improve survival outcomes for patients with multiple myeloma in earlier lines,” said Roberto Mina, M.D., an Associate Professor at the Winship Cancer Institute of Emory University, who consulted with the company. “These results will continue to transform the role of bispecifics in clinical decision-making as early as second line — offering a steroid-sparing, community-based therapy for patients across all practice settings, regardless of prior anti-CD38 exposure.”

Teclistamab works as a T-cell engager, a type of immunotherapy that acts as a bridge between the patient's own T-cells and cancerous myeloma cells. By binding to both CD3 on T-cells and the BCMA protein on myeloma cells, it directs the immune system to recognize and destroy the cancer. This "off-the-shelf" approach provides a more accessible alternative to personalized cell therapies like CAR-T, which require a complex and time-consuming manufacturing process.

Decoding the Landmark Data

The head-to-head comparison in the MajesTEC-9 study pitted teclistamab monotherapy against two established standard-of-care combinations: pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd). The results were overwhelmingly in favor of teclistamab across all major endpoints.

The 71 percent reduction in the risk of disease progression or death (PFS) is a statistic that has captured the attention of the oncology community. The median progression-free survival for patients on teclistamab was not even reached at the time of analysis, while it was just 8.2 months for those on standard care. Furthermore, nearly two-thirds (65.9%) of patients receiving teclistamab achieved a complete response or better, meaning signs of their cancer disappeared, compared to just 16.8% in the standard-of-care arm. This deep and durable response is a critical indicator of long-term disease control.

The overall survival (OS) benefit—a 40% reduction in the risk of death—is considered the gold standard in oncology trials and underscores the therapy's life-extending potential.

The safety profile was consistent with previous studies of teclistamab and the bispecific antibody class. While adverse events were common, they were generally manageable. Cytokine release syndrome (CRS), a known side effect of T-cell engaging therapies, occurred in 66% of patients but was predominantly low-grade and resolved without leading to treatment discontinuation. Infections were more common with teclistamab, but their frequency decreased over time. Importantly, patients remained on teclistamab for a median of 13.1 months, nearly double the 7.0-month duration for standard care, allowing them to derive a longer-term benefit from the treatment despite the side effects.

Reshaping the Clinical and Competitive Landscape

The success of teclistamab in an earlier-line setting is set to disrupt the established treatment algorithm for multiple myeloma and intensify competition in a rapidly evolving market. Currently, CAR-T therapies like Carvykti and Abecma are also moving into earlier lines of treatment, offering remarkable efficacy. However, their logistical hurdles—including vein-to-vein time and the need for specialized treatment centers—can limit access.

As a subcutaneous, off-the-shelf product, teclistamab offers a significant advantage in accessibility and can be administered in community oncology settings, bringing cutting-edge immunotherapy closer to where patients live. This convenience could make it a preferred option for many physicians and patients.

The data also reinforces Johnson & Johnson’s formidable strategy in the hematology space. This is the second positive Phase 3 study for teclistamab in earlier-line treatment, following the impressive results of the MajesTEC-3 trial presented at ASH 2025, which evaluated teclistamab in combination with daratumumab. With regulatory submissions already filed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the company is moving swiftly to make this new indication a reality for patients.

“As an established and convenient off-the-shelf bispecific antibody in advanced stages of relapsed or refractory multiple myeloma, teclistamab continues to build momentum across the treatment landscape," said Ester in ‘t Groen, EMEA Therapeutic Area Head, Haematology at Johnson & Johnson. "These latest data add further clinical evidence supporting the potential of teclistamab-based regimens to move into earlier lines of treatment and to become a potential new standard of care as early as the second line.”

The path to approval may be accelerated by evolving regulatory standards. The FDA has recently indicated a willingness to use endpoints like minimal residual disease (MRD) negativity to support accelerated approvals for myeloma drugs, recognizing the strong correlation with long-term survival. Given the high rates of deep responses seen with teclistamab, this regulatory flexibility could expedite its availability for this broader patient population. If approved, teclistamab would not only offer new hope to thousands of patients facing their first relapse but also solidify Johnson & Johnson's position as a leader in the fight against multiple myeloma.